Abstract 351P
Background
Waldenstrom macroglobulinemia (WM) is a very rare disease. It also known as lymphoplasmacytic lymphoma, a low grade-B cell lymphoproliferative neoplasm characterized by monoclonal IgM gammopathy. The diagnosis of WM is challenging and data regarding clinical features and treatment outcomes in Indonesia is limited. The aim of this study is to investigate clinical features, treatments and outcomes of WM patients in the tertiary referral cancer center in Jakarta, Indonesia.
Methods
This was a retrospective cohort study conducted in outpatient oncology clinic in a tertiary referral cancer center in Jakarta, Indonesia from 2022 until 2023. It included all patients with working diagnosis WM based on Waldenstrom Macroglobulinemia International Workshop Criteria. Demographic data, clinical features, treatments, and outcomes were collected.
Results
We evaluated a total of 8 patients. Most of the patients (62.5%) were male, with mean age 61.1 + 8.6 years old. All patients had symptoms of anemia such weakness, light-headedness, and shortness of breath. Median hemoglobin was 8.46 (6.0 – 13.1) g/dL. Mean immunoglobulin (Ig)M was 3832. Three (37.5%) patients had autoimmune hemolytic anemia (AIHA), and 3 (37.5%) patients had organomegaly. Seventy percent patients received systemic therapy, mostly (66.7%) with Cyclophosphamide Vincristine Prednisone (CVP) regiment. Among those who had systemic therapy, two (33.3%) patients died, and 1 (16.6%) patient transformed into acute myeloid leukemia (AML).
Conclusions
The clinical features of WM were male sex, elderly, anemia, had AIHA, high IgM and organomegaly. Most patients underwent systemic therapy but had unfavorable responses. Further studies should focus on predictors of survival on WM patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
529P - Ramucirumab plus docetaxel after combination chemoimmunotherapy in patients with non-small cell lung cancer: A prospective observational study
Presenter: Tadaaki Yamada
Session: Poster Display
Resources:
Abstract
530P - MYC recruits tumor-associated macrophage to sustain metastatic malignancy of lung adenocarcinoma micropapillary subtype through epigenetic reprogramming
Presenter: Xuming Song
Session: Poster Display
Resources:
Abstract
531P - Effect of combinational targeted therapy for AXL and ATR against malignant mesothelioma cells
Presenter: Soichi Hirai
Session: Poster Display
Resources:
Abstract
532P - The changes of the serum SMRP levels is useful to predict the antitumor efficacy of ipilimumab plus nivolumab combination therapy in patients with malignant pleural mesothelioma
Presenter: Taiichiro Otsuki
Session: Poster Display
Resources:
Abstract
533P - Efficacy in the elderly NSCLC patients in SCORPION study: Phase II study of DTX plus RAM following platinum-based chemotherapy plus ICIs
Presenter: Teppei Yamaguchi
Session: Poster Display
Resources:
Abstract
534P - DSC2 promotes the proliferation, metastasis and drug resistance of lung cancer by activating the PI3K/AKT pathway
Presenter: Qi Li
Session: Poster Display
Resources:
Abstract
535P - Alteration in NKX2-1 CN reshapes the oncogenic, immunologic, and prognostic landscapes in NSCLC
Presenter: Herdee Gloriane Luna
Session: Poster Display
Resources:
Abstract
536P - The evaluation and long-term outcome of pulmonary metastasectomy for osteosarcoma: A 20-year experience of Shanghai Rujin Hospital
Presenter: Zhusheng Zhang
Session: Poster Display
Resources:
Abstract
537P - The impact of treatment-free interval on patient outcome after pulmonary metastasectomy for sarcoma
Presenter: Po-Kuei Hsu
Session: Poster Display
Resources:
Abstract
538P - First-line chemoimmunotherapy for metastatic thymic carcinoma
Presenter: Victoria Andreas
Session: Poster Display
Resources:
Abstract